Vertex Pharmaceuticals Incorporated (VRTX)
Company Info
ISIN | US92532F1003 |
---|---|
CUSIP | 92532F100 |
Sector | Healthcare |
Industry | Biotechnology |
Highlights
Market Cap | $107.37B |
---|---|
EPS | $13.88 |
PE Ratio | 29.95 |
PEG Ratio | 0.56 |
Revenue (TTM) | $9.87B |
Gross Profit (TTM) | $5.32B |
EBITDA (TTM) | $4.48B |
Year Range | $309.43 - $448.40 |
Target Price | $428.29 |
Short % | 1.57% |
Short Ratio | 2.57 |
Share Price Chart
Loading data...
Compare to other instruments
Performance
Performance Chart
The chart shows the growth of an initial investment of $10,000 in Vertex Pharmaceuticals Incorporated, comparing it to the performance of the S&P 500 index or another benchmark. All prices have been adjusted for splits and dividends.
Returns By Period
Vertex Pharmaceuticals Incorporated had a return of 2.56% year-to-date (YTD) and 33.22% in the last 12 months. Over the past 10 years, Vertex Pharmaceuticals Incorporated had an annualized return of 19.97%, outperforming the S&P 500 benchmark which had an annualized return of 10.96%.
Period | Return | Benchmark |
---|---|---|
Year-To-Date | 2.56% | 10.04% |
1 month | -3.73% | 3.53% |
6 months | 19.35% | 22.79% |
1 year | 33.22% | 32.16% |
5 years (annualized) | 17.85% | 13.15% |
10 years (annualized) | 19.97% | 10.96% |
Monthly Returns Heatmap
Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
2024 | 6.51% | -2.92% | ||||||||||
2023 | -1.14% | -0.17% | 4.13% | -2.02% | 14.68% |
Risk-Adjusted Performance
Risk-Adjusted Performance Indicators
This table presents risk-adjusted performance metrics for Vertex Pharmaceuticals Incorporated (VRTX) and compares them with a selected benchmark (^GSPC). These performance indicators assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
Sharpe ratio | Sortino ratio | Omega ratio | Calmar ratio | Ulcer Index | |
---|---|---|---|---|---|
Vertex Pharmaceuticals Incorporated | 1.48 | ||||
S&P 500 | 2.76 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way.
Worst Drawdowns
The table below displays the maximum drawdowns of the Vertex Pharmaceuticals Incorporated. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Vertex Pharmaceuticals Incorporated was 91.77%, occurring on Nov 11, 2003. Recovery took 2677 trading sessions.
The current Vertex Pharmaceuticals Incorporated drawdown is 6.45%.
Depth | Start | To Bottom | Bottom | To Recover | End | Total |
---|---|---|---|---|---|---|
-91.77% | Nov 3, 2000 | 757 | Nov 11, 2003 | 2677 | Jul 2, 2014 | 3434 |
-81.22% | Jul 25, 1991 | 228 | Jun 18, 1992 | 993 | May 23, 1996 | 1221 |
-70.19% | Feb 25, 1997 | 383 | Aug 31, 1998 | 363 | Feb 8, 2000 | 746 |
-55.25% | Mar 7, 2000 | 29 | Apr 14, 2000 | 43 | Jun 16, 2000 | 72 |
-49.1% | Aug 20, 2015 | 340 | Dec 22, 2016 | 142 | Jul 19, 2017 | 482 |
Volatility
Volatility Chart
The current Vertex Pharmaceuticals Incorporated volatility is 5.14%, representing the average percentage change in the investments's value, either up or down over the past month. The chart below shows the rolling one-month volatility.
Financials
Financial Performance
Income Statement
TTM | |
---|---|
Revenue | |
Total Revenue | 0.00 |
Cost Of Revenue | 0.00 |
Gross Profit | 0.00 |
Operating Expenses | |
Selling, General & Admin Expenses | 0.00 |
R&D Expenses | 0.00 |
Total Operating Expenses | 0.00 |
Income | |
Income Before Tax | 0.00 |
Operating Income | 0.00 |
EBIT | 0.00 |
Earnings From Continuing Operations | 0.00 |
Net Income | 0.00 |
Income Tax Expense | 0.00 |
Interest Expense | 0.00 |
Other Non-Operating Income (Expenses) | 0.00 |
Extraordinary Items | 0.00 |
Discontinued Operations | 0.00 |
Effect Of Accounting Charges | 0.00 |
Non Recurring | 0.00 |
Minority Interest | 0.00 |
Other Items | 0.00 |